Zobrazeno 1 - 10
of 12
pro vyhledávání: '"Carmen de Ramon Ortiz"'
Publikováno v:
healthbook TIMES. Oncology Hematology, Vol 20, Iss 2 (2024)
Multiple myeloma (MM) is an incurable hematological malignancy of the plasma cells. Most patients with MM are older than 65 years. Therefore, it is highly important to perform a frailty assessment to identify which patients are especially vulnerable
Externí odkaz:
https://doaj.org/article/3a8a58b8607f4d99be043350b6352eba
Autor:
Federica Giannotti, Carmen De Ramon Ortiz, Federico Simonetta, Sarah Morin, Chiara Bernardi, Stavroula Masouridi-Levrat, Yves Chalandon, Anne-Claire Mamez
Publikováno v:
Frontiers in Immunology, Vol 15 (2024)
Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is a potentially curative treatment option for patients with highly chemorefractory Hodgkin lymphoma (HL). The CD30-targeting antibody-drug conjugate Brentuximab-Vedotin (BV) and programm
Externí odkaz:
https://doaj.org/article/cbfb749dbff44cd88f3e883f56499b63
Autor:
Carmen de Ramon Ortiz
Publikováno v:
healthbook TIMES. Oncology Hematology, Vol 9, Iss 3 (2021)
Externí odkaz:
https://doaj.org/article/5fa13c95d3ee48dd8706fc685793fe8a
Autor:
Yves Chalandon, Anne-Claire Mamez, Federica Giannotti, Yan Beauverd, Carole Dantin, Elif Mahne, Maria Mappoura, Fanette Bernard, Carmen de Ramon Ortiz, Caroline Stephan, Sarah Morin, Marc Ansari, Federico Simonetta, Stavroula Masouridi-Levrat
Publikováno v:
Transplantation and Cellular Therapy. 28:765.e1-765.e9
Sinusoidal obstruction syndrome (SOS), also known as hepatic veno-occlusive disease (VOD), is a well-known complication of allogeneic hematopoietic stem cell transplantation (HSCT) associated with a mortality rate of up to 85%. Defibrotide has shown
Publikováno v:
Revue Médicale Suisse. 15:2032-2038
Autor:
Stavroula Masouridi-Levrat, Carmen De Ramon Ortiz, Maria Mappoura, Elif Mahne, Sarah Morin, Yan Beauverd, Federica Giannotti, Anne-Claire Mamez, Sarah Noetzlin, Christian Ayer, Federico Simonetta, Isaline Verdon, Caroline Stephan, Yves Chalandon, Marta Fabra Urdiola, Thien-An Tran
Publikováno v:
Bone marrow transplantation, Vol. 56, No 9 (2021) pp. 2284-2286
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::342e5d1e508aff3186746cb90a168c6b
https://archive-ouverte.unige.ch/unige:160536
https://archive-ouverte.unige.ch/unige:160536
Autor:
Anne-Claire Mamez, Maria Anastasiou, Yan Beauverd, Laura Bounaix, Christian Ayer, Mitja Nabergoj, Caroline Stephan, Benjamin Bruno, Carmen De Ramon Ortiz, Federica Giannotti, Stavroula Masouridi-Levrat, Thien-An Tran, Yves Chalandon, Maria Mappoura, Elif Mahne, Sarah Morin, Anna Petropoulou
Publikováno v:
Biology of Blood and Marrow Transplantation (2020)
Outcomes of hematopoietic stem cell transplantation (HSCT) are influenced by comorbidities, disease type, and status at transplantation. Several prognostic scores can be used, such as the disease risk index (DRI) or the hematopoietic cell transplanta
Publikováno v:
Revue medicale suisse. 15(670)
Multiple myeloma (MM) is the third most common hematological cancer. MM is a proliferation of plasma cells Its incidence increases from 1 per 100 000 at 40 years to 40 per 100 000 at 80 years. Today, there are many treatment strategies for MM that go
Autor:
Maria Anastasiou, Laura Bounaix, Yves Chalandon, Sarah Morin, Federica Giannotti, Federico Simonetta, Paraskevi Stakia, Anna Petropoulou, Amandine Pradier, Christian Ayer, Mitja Nabergoj, Stavroula Masouridi-Levrat, Carmen De Ramon Ortiz, Yan Beauverd, Elif Mahne, Thien-An Tran, Maria Mappoura, Adrien Petitpas, Anne-Claire Mamez, Benjamin Bruno
Publikováno v:
Blood. 136:43-44
Introduction Allogeneic hematopoietic stem cell transplantation (HSCT) is a well-established therapeutic modality for a variety of hematological malignancies and congenital disorders. One of the major complications of the procedure is graft-versus-ho
Autor:
Federica Giannotti, Yves Chalandon, Federico Simonetta, Mitja Nabergoj, Carmen De Ramon Ortiz, Christian Ayer, Thien-An Tran, Caroline Stephan, Stavroula Masouridi-Levrat, Benjamin Bruno, Sarah Morin, Yan Beauverd, Anne-Claire Mamez, Elif Mahne, Maria Anastasiou, Laura Bounaix, Maria Mappoura, Anna Petropoulou
Publikováno v:
Blood. 136:19-20
Background: The AML EBMT Cytogenetic Risk score is a new prognostic model recently published (Canaani et al. Leukemia. 2019 Aug;33(8):1944-1952; Nagler el al. Am J Hematol. 2020 Jun 12) combining cytogenetics and FLT3ITD status for AML patients in co